… benefit compared with vitamin K antagonist for reducing the … of the relative efficacy and
safety of each NOAC versus VKA. … according to local practices and not in the confines of a …

… patients with atrial fibrillation (AF). Data on the safety and efficacy of Edoxaban in routine care
in Germany, … one-year outcomes in patients with AF treated with Edoxaban in routine care. …

… factor Xa inhibitor (rivaroxaban, apixaban, and edoxaban), have … Data from pivotal NOACs
studies including the German and … will be encountered more frequently in our daily practice. …

… with vitamin K antagonists (VKA) or non-vitamin K antagonist … bleeding occurred in the group
who received apixaban. … that VKA treatment is still popular in clinical practice mainly due to …

… to dabigatran during routine clinical practice were recruited and … patient satisfaction in
patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin …

… A relative reduction of the proportion of patients treated with low dosages was evident overtime
for dabigatran and rivaroxaban; whereas prescription of low dose apixaban … practice of …

… One ongoing trial in Germany is comparing apixaban to VKA [42]. … Vitamin K antagonists
for stroke prevention in hemodialysis patients with atrial fibrillation: a systematic review and meta…

… standard vitamin K antagonist (VKA) therapy for patients with … A sub-analysis from the
AUGUSTUS trial with apixaban … successful PCI in German routine clinical practice for up to 1 …

… , dabigatran and apixaban, each compared with vitamin K antagonist therapy. The model …
in patients with non-valvular atrial fibrillation (NVAF), and clinical practice guidelines …

… or vitamin K antagonists. HTA methods and information on … practice, likely due to its
established familiarity and lower … (Germany [50], France [35], and the Netherlands [apixaban and …